
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc is exhibiting a positive outlook due to its innovative approach to developing precision medicines for chronic kidney disease through its Compass platform, which utilizes variant functionalization to link genetic variants to disease pathways. The promising efficacy signals observed in the Phase 2 HORIZON trial for MZE829, combined with the favorable data from MZE782's Phase 1 trials, enhance the likelihood of achieving accelerated approval from regulators, potentially positioning the company for significant market entry advantages. Furthermore, the anticipated peak penetration increase of MZE829 in the treatment landscape demonstrates strong confidence in the company’s growth potential, bolstering its overall market appeal.
Bears say
Maze Therapeutics Inc faces significant risks regarding its investigational drug, inaxaplin, particularly pertaining to inflated efficacy signals that may result from treatment outcomes in diverse patient cohorts. The variability in patient response, such as a notable portion (25%) experiencing inadequate response to SGLT2 inhibitor therapies, raises concerns about the reliability of the company's therapeutic approaches in chronic kidney disease contexts. Moreover, the observed eGFR declines in patients suggest that without stabilization through adequate treatment regimens, the company's pipeline may experience severe setbacks, potentially leading to a 30% downside risk in stock performance.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares